Partner Fund Management
Latest statistics and disclosures from PFM Health Sciences's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LLY, CYTK, MRK, ABBV, VRTX, and represent 30.56% of PFM Health Sciences's stock portfolio.
- Added to shares of these 10 stocks: VRTX (+$61M), UHS (+$17M), AVTR (+$15M), PRAX (+$15M), SYK (+$14M), BSX (+$14M), ZBH (+$14M), BDX (+$11M), ELV (+$11M), Lantheus Hldgs Inc Note 2.62512/1 (+$11M).
- Started 9 new stock positions in ZBH, AVTR, EYPT, CLDX, VRTX, Lantheus Hldgs Inc Note 2.62512/1, PRAX, OM, BSX.
- Reduced shares in these 10 stocks: , Seagen (-$60M), , CYTK (-$54M), UNH (-$51M), ISRG (-$50M), , SNDX (-$46M), IRTC (-$46M), .
- Sold out of its positions in AKRO, RCUS, BMRN, BIIB, CAH, DXCM, EDIT, IRTC, ImmunoGen, NARI. LNTH, Point Biopharma Global, Praxis Precision Medicines I, SRPT, Seagen, VRDN, ALKS.
- PFM Health Sciences was a net seller of stock by $-720M.
- PFM Health Sciences has $1.7B in assets under management (AUM), dropping by -21.47%.
- Central Index Key (CIK): 0001442756
Tip: Access up to 7 years of quarterly data
Positions held by Partner Fund Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for PFM Health Sciences
PFM Health Sciences holds 63 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Eli Lilly & Co. (LLY) | 10.4 | $174M | 299k | 582.92 |
|
|
| Cytokinetics Com New (CYTK) | 8.8 | $147M | -26% | 1.8M | 83.49 |
|
| Merck & Co (MRK) | 3.9 | $65M | 596k | 109.02 |
|
|
| Abbvie (ABBV) | 3.8 | $63M | -18% | 407k | 154.97 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.6 | $61M | NEW | 149k | 406.89 |
|
| Humana (HUM) | 3.4 | $57M | -24% | 125k | 457.81 |
|
| Edwards Lifesciences (EW) | 3.4 | $56M | +5% | 740k | 76.25 |
|
| Becton, Dickinson and (BDX) | 2.9 | $49M | +29% | 200k | 243.83 |
|
| McKesson Corporation (MCK) | 2.7 | $45M | 98k | 462.98 |
|
|
| Tenet Healthcare Corp Com New (THC) | 2.7 | $45M | 589k | 75.57 |
|
|
| Centene Corporation (CNC) | 2.5 | $41M | -29% | 558k | 74.21 |
|
| Karuna Therapeutics Ord | 2.5 | $41M | -5% | 130k | 316.51 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 2.5 | $41M | 679k | 60.17 |
|
|
| Penumbra (PEN) | 2.4 | $39M | -19% | 156k | 251.54 |
|
| Axsome Therapeutics (AXSM) | 2.2 | $37M | -10% | 467k | 79.59 |
|
| Caribou Biosciences (CRBU) | 2.2 | $37M | -3% | 6.5M | 5.73 |
|
| Hca Holdings (HCA) | 2.0 | $34M | +4% | 125k | 270.68 |
|
| Argenx Se Sponsored Adr (ARGX) | 2.0 | $33M | -17% | 87k | 380.43 |
|
| Universal Hlth Svcs CL B (UHS) | 1.8 | $31M | +123% | 202k | 152.44 |
|
| Danaher Corporation (DHR) | 1.7 | $29M | -28% | 126k | 231.34 |
|
| Icon SHS (ICLR) | 1.7 | $29M | -52% | 102k | 283.07 |
|
| Thermo Fisher Scientific (TMO) | 1.6 | $27M | -17% | 51k | 530.79 |
|
| Iqvia Holdings (IQV) | 1.6 | $26M | -44% | 112k | 231.38 |
|
| Molina Healthcare (MOH) | 1.5 | $25M | -51% | 70k | 361.31 |
|
| Acadia Healthcare (ACHC) | 1.4 | $24M | -18% | 308k | 77.76 |
|
| Veeva Sys Cl A Com (VEEV) | 1.4 | $23M | 119k | 192.52 |
|
|
| Anthem (ELV) | 1.3 | $23M | +94% | 48k | 471.56 |
|
| Essa Pharma Com New (EPIX) | 1.3 | $22M | -22% | 3.3M | 6.60 |
|
| Inhibrx (INBX) | 1.2 | $20M | +86% | 538k | 38.00 |
|
| Immunovant (IMVT) | 1.2 | $20M | 473k | 42.13 |
|
|
| Day One Biopharmaceuticals I (DAWN) | 1.1 | $19M | -41% | 1.3M | 14.60 |
|
| Arcellx Common Stock (ACLX) | 1.1 | $19M | +39% | 335k | 55.50 |
|
| Stryker Corporation (SYK) | 1.1 | $18M | +384% | 59k | 299.46 |
|
| Nevro Corp Note 2.750% 4/0 (Principal) | 1.0 | $17M | 18M | 0.95 |
|
|
| Avantor (AVTR) | 0.9 | $15M | NEW | 677k | 22.83 |
|
| Biomarin Pharmaceutical Note 0.599% 8/0 (Principal) | 0.9 | $15M | 15M | 0.99 |
|
|
| Praxis Precision Medicines I Com New (PRAX) | 0.9 | $15M | NEW | 657k | 22.28 |
|
| Cytokinetics Note 3.500% 7/0 (Principal) | 0.8 | $14M | -68% | 8.0M | 1.76 |
|
| Boston Scientific Corporation (BSX) | 0.8 | $14M | NEW | 238k | 57.81 |
|
| Zimmer Holdings (ZBH) | 0.8 | $14M | NEW | 113k | 121.70 |
|
| Roivant Sciences SHS (ROIV) | 0.8 | $14M | 1.2M | 11.23 |
|
|
| Werewolf Therapeutics (HOWL) | 0.8 | $13M | +35% | 3.5M | 3.86 |
|
| Syndax Pharmaceuticals (SNDX) | 0.8 | $13M | -78% | 596k | 21.61 |
|
| Lantheus Hldgs Note 2.625%12/1 (Principal) | 0.6 | $11M | NEW | 9.5M | 1.13 |
|
| UnitedHealth (UNH) | 0.6 | $10M | -83% | 19k | 526.47 |
|
| Xenon Pharmaceuticals (XENE) | 0.5 | $8.9M | +145% | 193k | 46.06 |
|
| Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.5 | $8.3M | 10M | 0.79 |
|
|
| Intuitive Surgical Com New (ISRG) | 0.5 | $8.2M | -85% | 24k | 337.36 |
|
| Sana Biotechnology (SANA) | 0.5 | $7.7M | +51% | 1.9M | 4.08 |
|
| Prothena Corp SHS (PRTA) | 0.4 | $6.9M | -77% | 190k | 36.34 |
|
| Erasca (ERAS) | 0.3 | $5.5M | -34% | 2.6M | 2.13 |
|
| Outset Med (OM) | 0.3 | $5.4M | NEW | 999k | 5.41 |
|
| Pmv Pharmaceuticals (PMVP) | 0.3 | $4.6M | +13% | 1.5M | 3.10 |
|
| Io Biotech (IOBT) | 0.3 | $4.4M | +72% | 2.3M | 1.88 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.2 | $3.9M | NEW | 171k | 23.11 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.2 | $3.7M | 677k | 5.42 |
|
|
| Oscar Health Cl A (OSCR) | 0.2 | $3.1M | 336k | 9.15 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 0.2 | $3.0M | +540% | 339k | 8.75 |
|
| Bluebird Bio (BLUE) | 0.2 | $2.8M | -66% | 2.0M | 1.38 |
|
| Generation Bio (GBIO) | 0.2 | $2.7M | -35% | 1.6M | 1.65 |
|
| Celcuity (CELC) | 0.1 | $2.3M | -25% | 157k | 14.57 |
|
| Turnstone Biologics Corp (TSBX) | 0.1 | $1.6M | -58% | 633k | 2.54 |
|
| Celldex Therapeutics Com New (CLDX) | 0.1 | $1.4M | NEW | 35k | 39.66 |
|
Past Filings by PFM Health Sciences
SEC 13F filings are viewable for PFM Health Sciences going back to 2010
- PFM Health Sciences 2023 Q4 filed Feb. 14, 2024
- PFM Health Sciences 2023 Q3 filed Nov. 14, 2023
- PFM Health Sciences 2023 Q2 filed Aug. 14, 2023
- PFM Health Sciences 2023 Q1 filed May 15, 2023
- PFM Health Sciences 2022 Q4 filed Feb. 14, 2023
- PFM Health Sciences 2022 Q3 filed Nov. 14, 2022
- PFM Health Sciences 2022 Q2 filed Aug. 15, 2022
- PFM Health Sciences 2022 Q1 filed May 16, 2022
- PFM Health Sciences 2021 Q4 filed Feb. 14, 2022
- PFM Health Sciences 2021 Q3 filed Nov. 15, 2021
- PFM Health Sciences 2021 Q2 filed Aug. 16, 2021
- PFM Health Sciences 2021 Q1 filed May 17, 2021
- PFM Health Sciences 2020 Q4 restated filed Feb. 19, 2021
- PFM Health Sciences 2020 Q4 filed Feb. 16, 2021
- PFM Health Sciences 2020 Q3 filed Nov. 16, 2020
- Partner Fund Management 2020 Q2 filed Aug. 14, 2020